The cell-based matrices products are a new type of bone substitutes that was introduced to the US market in mid to late 2000s. Bone Morphogenetic Proteins (BMPs) are low molecular weight, non-collagenous glycoproteins. Allograft bone chips are the transplanted bones, sourced from a genetically non-identical living or dead member of the same species. The applications in the segment are based on the division of entire skeleton structure into Trauma for fractures -CMF for cranio maxillofacial (excluding the dental market which is covered within a different market) spinal fusions (since all spinal fusions will need some amount of bone graft usage), and joint reconstruction and replacements (including repairs) for large joints which includes hip and knee, and other joints which include shoulder, elbow, wrist, digit and ankle. Allograft Bone Chips, Bone Morphogenetic Proteins (BMP), Demineralized Bone Matrix (DBM), synthetic bone substitutes, and cell-based matrices are covered under this segment. Medical device companies can identify attractive segments in respective markets as well as develop marketing strategies based on forecasts for those segments.īone graft substitutes are synthetic substances which are an alternative to bone allografts and autografts. Understanding market size can be crucial to evaluate opportunities and make informed decisions about market entry and exit. In 2022, GlobalData’s Market Model methodology determined that the leading player in the bone grafts and substitutes market in Brazil was Bioventus followed by Medtronic, NuVasive, Osiris Therapeutics, Stryker and Zimmer Biomet. No representation is made as to the safety or effectiveness of 4D-310, 4D-125, or 4D-110 for the therapeutic use for which they are being studied.Bioventus Inc Medtronic Plc NuVasive Inc Osiris Therapeutics Inc Stryker Corp View all 4DMT is currently conducting three clinical trials: 4D-125 is in a Phase 1/2 clinical trial for XLRP patients, 4D-110 is in a Phase 1 clinical trial for choroideremia patients and 4D-310 is in a Phase 1/2 clinical trial for Fabry disease patients.ĤD Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.ĤD-310, 4D-125 and 4D-110 are our product candidates in clinical trials and have not yet been approved for marketing by the US FDA or any other regulatory authority. The 4DMT targeted and evolved vectors are invented with the goal of being delivered through clinically routine, well-tolerated and minimally invasive routes of administration, transducing diseased cells in target tissues efficiently, having reduced immunogenicity and, where relevant, having resistance to pre-existing antibodies. The company is initially focused in three therapeutic areas: ophthalmology, cardiology, and pulmonology. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector Evolution, which combines the power of directed evolution with approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Details of the fireside chat are as follows:Įvent: Chardan’s 5 th Annual Genetic Medicines ConferenceĪ live audio webcast of the fireside chat will be available by visiting the “Investors & Media” section of the 4DMT website at A replay of the webcast will be available for at least two weeks following the live event.ĤDMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 29, 2021 (GLOBE NEWSWIRE) - 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that management will participate in Chardan’s 5 th Annual Genetic Medicines Conference being held virtually on Monday, October 4.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |